Clearside Biomedical (CLSD) shares fell 31% in recent Friday trading after downgrades by at least five analysts.
Stifel downgraded the stock to neutral from buy and cut its price target to $2 from $8. Chardan lowered its rating to neutral from buy and withdrew its $6 price target. HC Wainwright, Needham and Jones Trading also issued downgrades.
Clearside's intraday volume topped 3.08 million shares versus the daily average of 238,151.
Price: 0.41, Change: -0.19, Percent Change: -31.37
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。